AR034203A1 - Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento - Google Patents

Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento

Info

Publication number
AR034203A1
AR034203A1 ARP020100210A ARP020100210A AR034203A1 AR 034203 A1 AR034203 A1 AR 034203A1 AR P020100210 A ARP020100210 A AR P020100210A AR P020100210 A ARP020100210 A AR P020100210A AR 034203 A1 AR034203 A1 AR 034203A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
aryl
independently
heteroaryl group
Prior art date
Application number
ARP020100210A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR034203A1 publication Critical patent/AR034203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de 1-aril- ó 1-alquilsulfonilbenzazol, que comprenden un compuesto de fórmula (1), en donde: W es SO2, CO, CONH, CSNH ó CH2; X es CR7 ó N; Y es CR8 ó N, con la condición que cuando X es N, entonces Y debe ser CR8; Z es O, SOp ó NR9; R1 y R2 son cada uno de manera independiente H o alquilo C1-6; n es un entero de 2, 3, ó 4; R3 y R4 son cada uno de manera independiente H, CNR10NR11R12 o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido, o R3 y R4 pueden tomarse junto con el átomo al cual están unidos, para formar un anillo de 3 a 6 miembros, opcionalmente sustituido, que contiene opcionalmente un heteroátomo adicional seleccionado entre O, N ó S; R5 es H, halógeno, CN, OR13, CO2R14, CONR15R16, CNR17NR18R19, SO2NR20R21, SOpR22, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, fenilo o heteroarilo, cada uno opcionalmente sustituido; m es un entero de 1, 2, ó 3; p y q son cada uno de manera independiente 0 ó un entero de 1 ó 2; R6 es un grupo alquilo C1-6 opcionalmente sustituido, arilo o heteroarilo; R7 y R8 son cada uno de manera independiente H, halógeno, o un grupo alquilo C1-6, arilo, heteroarilo, o alcoxi C1-6, cada uno opcionalmente sustituido; R9 es H, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R10, R11, R12, R15, R16, R17, R18 y R19 son cada uno de manera independiente H, o alquilo C1-4; R13 es H, COR23, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R14 es H, o un grupo alquilo C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R20 y R21 son cada uno de manera independiente H o un grupo alquilo C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; y R22 y R23 son cada uno de manera independiente un grupo alquilo C1-6 opcionalmente sustituido, arilo o heteroarilo; o una sal farmacéuticamente aceptable del mismo; un método para su preparación, una composición farmacéutica y el uso del mismo para el tratamiento terapéutico de desórdenes relacionados con, o afectados por el receptor de 5-HT6.
ARP020100210A 2001-01-23 2002-01-22 Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento AR034203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26342501P 2001-01-23 2001-01-23

Publications (1)

Publication Number Publication Date
AR034203A1 true AR034203A1 (es) 2004-02-04

Family

ID=23001722

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100210A AR034203A1 (es) 2001-01-23 2002-01-22 Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento

Country Status (23)

Country Link
US (4) US6509357B1 (es)
EP (1) EP1353904B9 (es)
JP (1) JP4208573B2 (es)
KR (1) KR20030068591A (es)
CN (1) CN1273450C (es)
AR (1) AR034203A1 (es)
AT (1) ATE312078T1 (es)
AU (1) AU2002251811B2 (es)
BR (1) BR0206633A (es)
CA (1) CA2435566A1 (es)
DE (1) DE60207815T2 (es)
DK (1) DK1353904T3 (es)
EA (1) EA006057B1 (es)
ES (1) ES2250638T3 (es)
HU (1) HUP0401009A3 (es)
IL (1) IL157059A0 (es)
MX (1) MXPA03006479A (es)
NO (1) NO20033300L (es)
NZ (1) NZ527051A (es)
PL (1) PL364568A1 (es)
TW (1) TW593278B (es)
WO (1) WO2002059088A1 (es)
ZA (1) ZA200306542B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112847099A (zh) * 2021-03-08 2021-05-28 王佳丽 一种有效调节进给量实现自动切割的砂轮切割机

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293073C (zh) * 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
NZ529631A (en) * 2001-06-07 2006-08-31 F Indole derivatives with 5-hydroxytryptamine (5-HT) 5-HT6 receptor affinity in the treatment of disorders of the CNS
AU2003209114A1 (en) * 2002-02-14 2003-09-04 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
BR0311593A (pt) * 2002-06-05 2005-04-26 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
WO2004026837A2 (en) * 2002-09-18 2004-04-01 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
BR0316962A (pt) 2002-12-03 2005-10-25 Hoffmann La Roche Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc
RU2347780C2 (ru) * 2003-02-14 2009-02-27 Уайт Гетероциклил-3-сульфонилиндазолы в качестве лигандов 5-гидрокситриптамина-6
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
EP1737865A1 (en) 2004-02-27 2007-01-03 F.Hoffmann-La Roche Ag Fused derivatives of pyrazole
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2815734C (en) * 2004-10-08 2015-06-30 I-Con Systems, Inc. Diaphragm valve with electronic pressure detection
DE602005011844D1 (de) 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
AU2006280091A1 (en) * 2005-08-15 2007-02-22 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
AU2006283941A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
MY151835A (en) 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof
MX2008012824A (es) * 2006-04-05 2008-10-15 Wyeth Corp Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6.
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
CA2650082A1 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
US20090023925A1 (en) * 2007-06-28 2009-01-22 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
CN105541693B (zh) 2014-07-08 2018-10-16 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
JP7187449B2 (ja) 2016-09-30 2022-12-12 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
AU2018254577B2 (en) 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
AU2018360766A1 (en) 2017-11-06 2020-05-21 Rapt Therapeutics, Inc. Anticancer agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2905877A1 (de) * 1979-02-16 1980-08-28 Boehringer Mannheim Gmbh Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5889022A (en) 1993-12-21 1999-03-30 Smithkline Beecham, P.L.C. Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity
GB9416972D0 (en) * 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
GB9600344D0 (en) 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
JP2000501107A (ja) * 1996-01-09 2000-02-02 イーライ・リリー・アンド・カンパニー ベンズイミダゾリル神経ペプチドｙ受容体アンタゴニスト
AU2139097A (en) * 1996-03-01 1997-09-16 Eli Lilly And Company Methods of treating or preventing sleep apnea
WO1998030548A1 (fr) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE
US6127380A (en) 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5872144A (en) 1997-02-18 1999-02-16 American Home Products Corporation 4-aminoethoxyindazole derivatives
HUP0101468A2 (hu) 1998-03-31 2001-08-28 Du Pont Pharmaceuticals Company Angiogenetikus rendellenességek leképzésére alkalmas szerek
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
TR200101775T2 (tr) * 1998-12-18 2002-07-22 Dupont Pharmaceuticals Company Vitronektin alıcı antagonist farmasötikler
GB9902452D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112847099A (zh) * 2021-03-08 2021-05-28 王佳丽 一种有效调节进给量实现自动切割的砂轮切割机

Also Published As

Publication number Publication date
KR20030068591A (ko) 2003-08-21
HUP0401009A2 (hu) 2004-08-30
DK1353904T3 (da) 2006-02-20
ZA200306542B (en) 2005-11-21
IL157059A0 (en) 2004-02-08
CA2435566A1 (en) 2002-08-01
US6710069B2 (en) 2004-03-23
EP1353904B9 (en) 2006-05-03
EA200300829A1 (ru) 2003-12-25
ATE312078T1 (de) 2005-12-15
AU2002251811B2 (en) 2007-06-21
WO2002059088A1 (en) 2002-08-01
US20040087637A1 (en) 2004-05-06
EP1353904A1 (en) 2003-10-22
US6919354B2 (en) 2005-07-19
US20030149018A1 (en) 2003-08-07
TW593278B (en) 2004-06-21
NZ527051A (en) 2005-07-29
EP1353904B1 (en) 2005-12-07
ES2250638T3 (es) 2006-04-16
CN1273450C (zh) 2006-09-06
NO20033300L (no) 2003-09-03
PL364568A1 (en) 2004-12-13
EA006057B1 (ru) 2005-08-25
US6509357B1 (en) 2003-01-21
JP4208573B2 (ja) 2009-01-14
CN1498209A (zh) 2004-05-19
BR0206633A (pt) 2004-02-17
US20040092564A1 (en) 2004-05-13
HUP0401009A3 (en) 2004-10-28
NO20033300D0 (no) 2003-07-22
MXPA03006479A (es) 2003-09-22
DE60207815D1 (de) 2006-01-12
JP2004521116A (ja) 2004-07-15
DE60207815T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR034270A1 (es) 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR034283A1 (es) Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
AR033306A1 (es) Compuestos
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR077505A1 (es) Compuestos de piridina y sus usos
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
NO20085078L (no) Nye forbindelser
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
AR075587A1 (es) Derivados de bifenilo para el tratamiento de hepatitis c
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
NO20051223L (no) Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5.
NO20090328L (no) Nye forbindelser 385
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20081689A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal